Verastem Inc (NASDAQ:VSTM), which focuses on developing drugs to treat cancer by the targeted killing of cancer stem cells, said its Q3 net loss widened on higher expenses, including stock based compensation and research and development costs. The net loss for the 2014 quarter was $13.3 million, or $0.52 per share, as compared to net loss of $10.6 million, or $0.44 per share, for the same period in 2013. That's in line with analysts' estimates.R&D costs rose to $9.0 million compared to $6.8 million a year ago and general and administrative expenses were $4.3 million compared to $3.9 million. There was an increase of $71,000 in stock-based compensation costs. As of September 30, 2014, Verastem Inc (NASDAQ:VSTM) had cash, cash equivalents and investments of $93.4 million compared to $123.7 million on December 31, 2013. Based on current operating plans, the company expects to have sufficient cash, cash equivalents and investments to fund our research and development programs and operations into the first half of 2016. The shares have a 52-week spread of $7.10 - $16.60.Time Warner Cable Inc (NYSE:TWC) Thursday reported a marginally lower net income attributable to shareholders of $499 million, or $1.77 per share, in Q3 ended September 30 compared to $532 million, or $1.86 per share, a year earlier. But after adjustments, profit was higher at $527 million, or $1.86 per share, versus Street view of $1.91 and last year's $489 million, or $1.69 per share. Time Warner Cable Inc (NYSE:TWC) revenue grew 3.6% year-over-year to $5.71 billion, slightly below the Capital IQ consensus of $5.75 billion, as a result of revenue growth at all segments. Business services revenue was up 21.9% and residential high-speed data revenue rose 10.9%. During the quarter, business services added more than 16,000 commercial buildings to its network expanding its serviceable market opportunity by over $250 million per year. Total high-speed data net also added 108,000, which marks the best Q3 performance in five years.CIGNA Corporation (NYSE:CI) Thursday reported stronger-than-forecast earnings and revenues for Q3 ended September 30, owing to growth in premiums and fees in its targeted customer segments. The health insurance company outperformed the Capital IQ consensus of EPS of $1.82 and revenues of $8.66 billion with adjusted net income of $519 million, or $1.95 per share, on revenues of $8.8 billion during the quarter. A year ago, adjusted net income was $536 million, or $1.89 per share, on revenues of $8.1 billion.Revenues reflect growth in premiums and fees of 7% in global health care, 17% in global supplemental benefits, and 7% in group disability and life, primarily driven by continued growth in Cigna's targeted customer segments. Given stronger quarterly performance in Q3, Cigna expects to earn, on an adjusted basis, $1.95 billion to $2.00 billion, or $7.25 to $7.45 per share. The market's call is for adjusted EPS of $7.34, according to Capital IQ. CIGNA Corporation (NYSE:CI) has a 52-week range of $73.47 - $97.28.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
